Fumio Teramae

Dr. Fumio Teramae

Eli Lilly and Company
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2020 in Sustainability
Verified
Journal Article
Open access
PDF file
FTFumio Teramae
Fumio Teramae
TMTomohiro Makino
Tomohiro Makino
YLyeongjoo lim
yeongjoo lim
Shintaro SengokuShintaro Sengoku
Shintaro Sengoku
Kota KodamaKota Kodama
Kota Kodama
Although it is generally agreed that the pharmaceutical industry is in a state of rapid internationalization, there is no clear comprehensive explanation of the current state and effectiveness of an international strategy. There are many studies about internationalization but they neither focus on the pharmaceutical industry nor evaluate the effectiveness of an international strategy with a control. Therefore, we investigate the current state of internationalization with a sample of the 30 multinational pharmaceutical companies, as well as the effectiveness of an international strategy by comparing two international strategies. In this study, we define an international strategy as a strategy that controls the geographic distribution of sales across regions to maximize total sales. The results show that 33% of the companies are still home-region-oriented, and we did not find any evidence of the effectiveness of an international strategy that pursues a balanced geographic distribution across regions in terms of total sales and adjusted total sales. The results provide the practical implication that pharmaceutical companies should weigh up the specific markets to secure higher sales through the advantage of adapting to customers’ needs. This paper contributes to the research on sustainable growth by empirically providing results of comparisons of different international strategies in the pharmaceutical industry.

2 July 2020 in Sustainability
Verified
Journal Article
Open access
PDF file
FTFumio Teramae
Fumio Teramae
TMTomohiro Makino
Tomohiro Makino
YLyeongjoo lim
yeongjoo lim
Shintaro SengokuShintaro Sengoku
Shintaro Sengoku
Kota KodamaKota Kodama
Kota Kodama
Research and development (R&D) productivity is continuously declining, and it is said that the conventional model of pharmaceutical business is becoming obsolete. Many research studies on R&D productivity focus on inputs (e.g., strategic transactions to absorb external innovation, R&D expenditures), outputs (e.g., approvals of a new drug), and outcomes (e.g., total sales, incomes). However, few prior studies address the relationship among these three components simultaneously. Therefore, we comprehensively analyzed factors affecting R&D productivity by statistically examining a sample of 30 large multinational companies. Our results show that strategic transactions do not increase the number of approved drugs and negatively affect growth in terms of total sales. Additionally, our results show that a home-region-oriented international strategy positively affects total sales, thus indicating that responsiveness to local medical needs is important for sustainable growth. This paper contributes to the body of research on R&D productivity in the pharmaceutical industry.

27 October 2020 in Sustainability
Verified
Journal Article
Open access
PDF file
FTFumio Teramae
Fumio Teramae
TMTomohiro Makino
Tomohiro Makino
Shintaro SengokuShintaro Sengoku
Shintaro Sengoku
YLyeongjoo lim
yeongjoo lim
TNTakashi Natori
Takashi Natori
Kota KodamaKota Kodama
Kota Kodama
An important agenda of pharmaceutical companies is the establishment of therapeutic area strategies, drug modality, and geographic strategies for research and development. It is worthwhile to understand the changes in therapeutic area, modality and internationalization of the top-selling pharmaceutical drugs over the past. Hence, the purposes of this study are to investigate changes in therapeutic area, modality and internationalization of the top-selling drugs and to identify their life cycle patterns. We compared the top-selling drugs between 2011 and 2017, and found that the percentages of nichebuster cancer drugs and home region-oriented drugs have increased whereas the proportions of traditional blockbuster cardiovascular drugs and global drugs have decreased. We compared product life cycle patterns via a Kruskal–Wallis test, and identified the features of product life cycle patterns per therapeutic area and modality. We performed a case study on drugs in the same class with the same pharmacological mechanism but found no differences across cases. Our results provide insights into therapeutic area strategies that consider life cycle patterns and geographic strategies that consider the competitive advantages of home region-oriented drugs. Finally, we presented new and simple models of life cycle patterns. This approach may help such enterprises establish and maintain sustainable growth.

1 February 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
FTFumio Teramae
Fumio Teramae
NYNaoya Yamaguchi
Naoya Yamaguchi
TMTomohiro Makino
Tomohiro Makino
Shintaro SengokuShintaro Sengoku
Shintaro Sengoku
Kota KodamaKota Kodama
Kota Kodama